Juckel G, Mavrogiorgou P, Bredemeier S, Gallinat J, Frodl T, Schulz C, Möller H-J, Hegerl U
Section of Clinical Neurophysiology, Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany.
Pharmacopsychiatry. 2004 Mar;37(2):46-51. doi: 10.1055/s-2004-815524.
Lithium has been found to be very effective in prophylactic treatment of affective disorders. However, approximately one-third of patients do not respond to this treatment, which does not become apparent until after a year or more of treatment. Therefore, predictors are needed to avoid a long and unsuccessful therapy with risk of severe side effects. Since lithium acts as a serotonin agonist in prophylactic treatment, a predictor of being able to identify patients with low serotonergic activity, who may be responders to lithium, is promising. To determine whether the loudness dependence (LDAEP) of primary, but not of secondary, auditory-cortex-evoked activity, which is inversely related to central serotonergic neurotransmission, could be such a predictor, responders and non-responders to prophylactic lithium treatment were compared.
Thirty patients with uni- and bipolar affective disorders, who have taken a prophylactic lithium medication continuously for at least 3 years, were included in the study. Patients were classified as responders if they had no hospitalization within the past 3 years. Dipole source analysis allowing us to separate evoked activity of the primary and secondary auditory cortex was used.
The LDAEP of the primary, but not of the secondary, auditory cortex was significantly stronger in the responders to the lithium treatment than in the non-responders, implicating low serotonergic function in these patients.
This finding, which is in line with previous studies, suggests that loudness dependence of primary auditory-cortex-evoked activity could be a clinically relevant predictor of prophylactic treatment with lithium in affective disorders.
锂已被发现对情感障碍的预防性治疗非常有效。然而,约三分之一的患者对这种治疗没有反应,这种情况直到治疗一年或更长时间后才会显现出来。因此,需要预测指标来避免长期且无效的治疗以及严重副作用的风险。由于锂在预防性治疗中作为5-羟色胺激动剂起作用,能够识别5-羟色胺能活性低且可能对锂有反应的患者的预测指标很有前景。为了确定与中枢5-羟色胺能神经传递呈负相关的初级而非次级听觉皮层诱发活动的响度依赖性(LDAEP)是否可以作为这样一种预测指标,对预防性锂治疗的反应者和无反应者进行了比较。
本研究纳入了30例单相和双相情感障碍患者,他们连续服用预防性锂药物至少3年。如果患者在过去3年内未住院,则被归类为反应者。使用偶极子源分析来分离初级和次级听觉皮层的诱发活动。
锂治疗反应者的初级听觉皮层而非次级听觉皮层的LDAEP明显强于无反应者,这表明这些患者的5-羟色胺能功能较低。
这一发现与先前的研究一致,表明初级听觉皮层诱发活动的响度依赖性可能是情感障碍锂预防性治疗的一个临床相关预测指标。